Eagle Pharmaceuticals Stock Forecast, Price & News

-0.04 (-0.09 %)
(As of 04/16/2021 04:00 PM ET)
Today's Range
Now: $44.27
50-Day Range
MA: $43.08
52-Week Range
Now: $44.27
Volume111,947 shs
Average Volume124,162 shs
Market Capitalization$585.12 million
P/E Ratio126.49
Dividend YieldN/A
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to treat organophosphate exposure; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has a strategic collaboration with Tyme Technologies, Inc. to advance oral SM-88 for the treatment of patients with cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Eagle Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:EGRX
Year FoundedN/A



Sales & Book Value

Annual Sales$195.89 million
Cash Flow$1.61 per share
Book Value$13.11 per share


Net Income$14.31 million


Market Cap$585.12 million
Next Earnings Date5/10/2021 (Estimated)


EGRX Mar 2021 45.000 call
March 20, 2021 |
EGRX Mar 2021 50.000 put
March 20, 2021 |
EGRX Jun 2021 50.000 put
March 20, 2021 |
EGRX Mar 2021 65.000 call
March 20, 2021 |
Earnings Preview: Eagle Pharmaceuticals
March 1, 2021 |
February 2, 2021 |
See More Headlines


Overall MarketRank

1.24 out of 5 stars

Medical Sector

885th out of 2,024 stocks

Pharmaceutical Preparations Industry

418th out of 772 stocks

Analyst Opinion: 1.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
-0.04 (-0.09 %)
(As of 04/16/2021 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EGRX News and Ratings via Email

Sign-up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Eagle Pharmaceuticals (NASDAQ:EGRX) Frequently Asked Questions

Is Eagle Pharmaceuticals a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Eagle Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EGRX, but not buy additional shares or sell existing shares.
View analyst ratings for Eagle Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Eagle Pharmaceuticals?

Wall Street analysts have given Eagle Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Eagle Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Eagle Pharmaceuticals' next earnings date?

Eagle Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Eagle Pharmaceuticals

How were Eagle Pharmaceuticals' earnings last quarter?

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) announced its quarterly earnings data on Monday, March, 1st. The specialty pharmaceutical company reported $0.96 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.42) by $2.38. The specialty pharmaceutical company had revenue of $49.92 million for the quarter, compared to analyst estimates of $50.08 million. Eagle Pharmaceuticals had a net margin of 2.65% and a trailing twelve-month return on equity of 8.50%.
View Eagle Pharmaceuticals' earnings history

How has Eagle Pharmaceuticals' stock price been impacted by Coronavirus?

Eagle Pharmaceuticals' stock was trading at $39.07 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, EGRX stock has increased by 13.3% and is now trading at $44.27.
View which stocks have been most impacted by COVID-19

What price target have analysts set for EGRX?

1 brokerages have issued 12-month price targets for Eagle Pharmaceuticals' stock. Their forecasts range from $46.00 to $46.00. On average, they anticipate Eagle Pharmaceuticals' stock price to reach $46.00 in the next twelve months. This suggests a possible upside of 3.9% from the stock's current price.
View analysts' price targets for Eagle Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Eagle Pharmaceuticals' key executives?

Eagle Pharmaceuticals' management team includes the following people:
  • Mr. Scott L. Tarriff, Founder, Pres, CEO & Director (Age 61, Pay $2.33M)
  • Mr. David M. Pernock, Chief Operating Officer (Age 68, Pay $1.28M)
  • Mr. Brian Joseph Cahill, Chief Financial Officer
  • Mr. Michael W. Cordera, Exec. VP, Gen. Counsel & Chief Compliance Officer
  • Mr. Daniel O'Connor, Exec. VP, Chief Strategy Officer & Head of Corp. Devel. (Age 41)
  • Mr. Michael Moran, Exec. VP and Head of Sales, Bus. Devel. & Gov. Affairs
  • Dr. Judith Ng-Cashin, Exec. VP & Chief Medical Officer
  • Mr. John Kimmet, Exec. VP of Marketing Oncology & Acute Care
  • Dr. Valentin R. Curt M.D., Sr. VP of Clinical Drug Devel.
  • Dr. Gaozhong Zhu Ph.D., Sr. VP of Pharmaceutical Devel.

Who are some of Eagle Pharmaceuticals' key competitors?

What other stocks do shareholders of Eagle Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Gilead Sciences (GILD), Exelixis (EXEL), Teekay Tankers (TNK), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Radius Health (RDUS), bluebird bio (BLUE), Clovis Oncology (CLVS), GW Pharmaceuticals (GWPH) and Incyte (INCY).

What is Eagle Pharmaceuticals' stock symbol?

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

Who are Eagle Pharmaceuticals' major shareholders?

Eagle Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Scout Investments Inc. (1.11%), Pacer Advisors Inc. (0.10%) and State of Alaska Department of Revenue (0.06%). Company insiders that own Eagle Pharmaceuticals stock include Douglas L Braunstein and Hudson Executive Capital Lp.
View institutional ownership trends for Eagle Pharmaceuticals

Which major investors are selling Eagle Pharmaceuticals stock?

EGRX stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue.
View insider buying and selling activity for Eagle Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Eagle Pharmaceuticals stock?

EGRX stock was purchased by a variety of institutional investors in the last quarter, including Scout Investments Inc., and Pacer Advisors Inc..
View insider buying and selling activity for Eagle Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Eagle Pharmaceuticals?

Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eagle Pharmaceuticals' stock price today?

One share of EGRX stock can currently be purchased for approximately $44.27.

How much money does Eagle Pharmaceuticals make?

Eagle Pharmaceuticals has a market capitalization of $585.12 million and generates $195.89 million in revenue each year. The specialty pharmaceutical company earns $14.31 million in net income (profit) each year or $1.38 on an earnings per share basis.

How many employees does Eagle Pharmaceuticals have?

Eagle Pharmaceuticals employs 108 workers across the globe.

What is Eagle Pharmaceuticals' official website?

The official website for Eagle Pharmaceuticals is

Where are Eagle Pharmaceuticals' headquarters?

Eagle Pharmaceuticals is headquartered at 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677.

How can I contact Eagle Pharmaceuticals?

Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at 201-326-5300 or via email at [email protected]

This page was last updated on 4/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.